MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
MANNKIND CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.09+0.05 (+1.64%)
Close on Oct 19, 2026
- Market cap
- $955.40M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.38 (−43.51%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
MANNKIND CORP grew revenue 30.5% to $393.63M over the twelve months to Jun 30, 2026. Operating income fell 86.2% to $9.19M, moving the operating margin from 22.2% to 2.3%. Free cash flow was -$18.14M, down 163.0% from a year earlier.
Revenue
$393.63M
+30.5% vs. a year earlier
Operating income
$9.19M
-86.2% vs. a year earlier
Free cash flow
-$18.14M
-163.0% vs. a year earlier
EPS, diluted
-$0.13
-218.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $955.40M
- P/E ratio
- –
- Price to sales
- 2.43
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1.90%
Fundamentals
- Revenue
- $393.63M
- Net income
- -$43.61M
- EPS, diluted
- -$0.13
- Free cash flow
- -$18.14M
- Book value per share
- -$0.22
- Diluted shares
- 309M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$393.63M+30.5% YoY
Gross profit
$353.29M+23.8% YoY
Operating income
$9.19M-86.2% YoY
Net income
-$43.61M-233.0% YoY
EPS, diluted
-$0.13-218.2% YoY
Free cash flow
-$18.14M-163.0% YoY
Reported periodTrailing twelve months